FDA Eyes Sanofi Antibiotic Over Safety Concerns

Law360, New York (November 15, 2006, 12:00 AM EST) -- The U.S. Food and Drug Administration has asked a joint panel of outside experts to turn the spotlight on a bronchitis treatment marketed by pharmaceutical giant Sanofi-Aventis SA amid concerns over the antibiotic’s possible link to severe liver problems and several deaths.

The agency said in a federal notice on Tuesday that it wants the panel to discuss the overall risks and benefits of Ketek – also known as also telithromycin – during a meeting on Dec. 14 and 15. The two-day review could result in...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.